With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a...
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatmentsLEHI,...
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at...
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
New panel will enable rapid, precise genetic profiling of patients with deadly diseaseNEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE)...
MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced...
Annual report indicates noticeable impact on prescription medications post-pandemic with clear link to declining mental health TELUS Health 2023 Drug...
A sponsored session will feature Dr. Alex Hastie from Bionano, Dr. Suk See De Ravin from National Institute of Health...
- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT),...
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of...
Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the...
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel...
Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules)...
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion...
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment...
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced...
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE)...
SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...